Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
378
Recruiting Now
378
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT06568094 Phase 1, Phase 2
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Adv...
Condition
Prostate Cancer
Enrollment
100 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co.,
NCT06265727 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
348 pts
Location
United States, France, Italy
Sponsor
Corbus Pharmaceuticals Inc.
NCT06484829 Phase 1, Phase 2
Recruiting
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethaso...
Condition
Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment
144 pts
Location
China
Sponsor
Chengdu Zenitar Biomedical Tec
NCT06024824 Phase 1, Phase 2
Recruiting
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
Condition
Pancreatic Adenocarcinoma
Enrollment
49 pts
Location
Ireland
Sponsor
Cancer Trials Ireland
NCT07186842 Phase 1, Phase 2
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentia...
Condition
Advanced Solid Cancers
Enrollment
245 pts
Location
United States, Australia, Germany
Sponsor
BioNTech SE
NCT05824169 Phase 1, Phase 2
Recruiting
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spina...
Condition
Spinal Muscular Atrophy
Enrollment
18 pts
Location
China
Sponsor
GeneCradle Inc
NCT07322094 Phase 1, Phase 2
Recruiting
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Che...
Condition
FIGO Stage III and IV Ovarian Cancer
Enrollment
60 pts
Location
United States
Sponsor
TORL Biotherapeutics, LLC
NCT06099379 Phase 1, Phase 2
Recruiting
Modulation of THC Effects by CBD: a Dose-ranging Study
Condition
Cannabis
Enrollment
100 pts
Location
Canada
Sponsor
Centre hospitalier de l'Univer
NCT05120596 Phase 1, Phase 2
Recruiting
First in Human Study of T3P-Y058-739 (T3P)
Condition
Advanced Solid Tumor
Enrollment
100 pts
Location
Spain, Switzerland, United Kingdom
Sponsor
T3 Pharmaceuticals AG
NCT04443010 Phase 1, Phase 2
Recruiting
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients Wi...
Condition
Glioblastoma
Enrollment
226 pts
Location
Switzerland
Sponsor
Philogen S.p.A.
NCT04802759 Phase 1, Phase 2
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in...
Condition
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Enrollment
316 pts
Location
United States, Australia, Israel
Sponsor
Hoffmann-La Roche
NCT07396155 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy i...
Condition
Diabetic Nephropathy Type 2
Enrollment
10 pts
Location
Indonesia
Sponsor
PT. Prodia Stem Cell Indonesia
NCT05435248 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Ce...
Condition
Advanced or Metastatic NSCLC
Enrollment
354 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical
NCT04299191 Phase 1, Phase 2
Recruiting
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan...
Condition
High-grade Glioma
Enrollment
28 pts
Location
United States
Sponsor
Laminar Pharmaceuticals
NCT07098806 Phase 1, Phase 2
Recruiting
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Le...
Condition
Leptomeningeal Metastasis
Enrollment
24 pts
Location
United States
Sponsor
Cerenome
NCT06809998 Phase 1, Phase 2
Recruiting
COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty
Condition
Total Knee Anthroplasty
Enrollment
60 pts
Location
Canada
Sponsor
Unity Health Toronto
NCT05947487 Phase 1, Phase 2
Recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07317544 Phase 1, Phase 2
Recruiting
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With a...
Condition
Androgenetic Alopecia (AGA)
Enrollment
227 pts
Location
Australia
Sponsor
Absci Pty Ltd.
NCT06741644 Phase 1, Phase 2
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Condition
Advanced Solid Tumors
Enrollment
800 pts
Location
United States, Australia, China
Sponsor
CStone Pharmaceuticals
NCT05426252 Phase 1, Phase 2
Recruiting
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Condition
Thalassemia in Children
Enrollment
20 pts
Location
Canada
Sponsor
The Hospital for Sick Children
NCT06561152 Phase 1, Phase 2
Recruiting
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refrac...
Condition
Refractory Acute Myeloid Leukemia
Enrollment
20 pts
Location
United States
Sponsor
Stanford University
NCT06546111 Phase 1, Phase 2
Recruiting
Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hespe...
Condition
Helicobacter Pylori Infection
Enrollment
46 pts
Location
Egypt
Sponsor
Sadat City University
NCT06642792 Phase 1, Phase 2
Recruiting
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymp...
Condition
Classic Hodgkin Lymphoma
Enrollment
280 pts
Location
China
Sponsor
Akeso
NCT07102004 Phase 1, Phase 2
Recruiting
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Condition
Advanced/Metastatic Solid Tumors
Enrollment
515 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
NCT06217757 Phase 1, Phase 2
Recruiting
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line...
Condition
Lung Cancer
Enrollment
45 pts
Location
China
Sponsor
Sichuan University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology